Safety and Efficacy of Klotho and Follistatin Gene Therapy

Part of paid clinical trials in Austin, Texas.

Sponsor
Minicircle
Study ID
NCT07285629
Phase
EARLY_PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Healthy Adults

Eligibility Criteria

Sex
ALL
Age
50 Years - 80 Years
Healthy Volunteers
Accepted

Interventions

  • Follistatin and klotho gene therapy — GENETIC
    Injection of nonviral plasmid-delivered follistatin and klotho gene therapy

Study Details

The purpose of this study is to investigate the safety and efficacy of a combination klotho and follistatin gene therapy, delivered via a nonviral plasmid in healthy adult volunteers. Additionally, this study seeks to understand the cognitive and health benefits of this gene therapy.

Key Dates

Start date
Dec 16, 2025
Status verified
Dec 2025
Primary completion
Jun 30, 2026
Completion
Jun 30, 2026

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION

Arms

  • Experimental: Intervention with Cognitive/Health battery before and after
    This arm includes cognitive and health battery pre- and post-intervention of the gene therapy

Primary Outcome Measure

Concentration of Serum α-Klotho Measured by Enzyme-Linked Immunosorbent Assay (ELISA) (pg/mL) [ Time Frame: From 1 month prior to treatment to 3 months after treatment (5 timepoints) ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Apeiron CenterAustinTexas78701
Mac Davis
[email protected]
512-630-0882

Find similar trials in Austin, TX

By research site
Apeiron Center· Austin, TX

Related Studies